Celtaxsys company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

celtaxsys.com

Total Raised

$52.7M

Deal Terms

1

Celtaxsys Funding, Celtaxsys Valuation & Celtaxsys Revenue

6 Fundings

Celtaxsys's latest funding round was a Series E for on January 4, 2018.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/4/2018

Series E

0

FY undefined

1

6/8/2015

Series D

$99M

0

FY undefined

10

6/8/2015

Grant

$99M

0

FY undefined

10

5/22/2009

Series C

$99M

0

FY undefined

0

5/8/2008

Series B

0

FY undefined

0

Date

1/4/2018

6/8/2015

6/8/2015

5/22/2009

5/8/2008

Round

Series E

Series D

Grant

Series C

Series B

Amount

$99M

$99M

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

0

0

Celtaxsys Deal Terms

1 Deal Term

Celtaxsys's deal structure is available for 1 funding round, including their Series D from June 08, 2015.

Round

Series D

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

$99M

Conversion Price

Anti Dilution

$99M

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

You May Also Like

H
Halsa Pharmaceuticals

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

L
LeukoSight

LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

XOMA Logo
XOMA

XOMA (NASDAQ: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. The Company is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. XOMA's product candidates are the result of developing monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

Kylin Therapeutics Logo
Kylin Therapeutics

Kylin Therapeutics, a biotechnology company, employs a RNA nanoparticle technology platform called"pRNA" to exploit the potential of RNA interference (RNAi) for treatment of many common diseases including cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.